T-Cell Lymphoma and Dupixent Lawsuits
Diagnosed With a T-Cell Lymphoma After Taking Dupixent?
The Dupixent lawsuits center on cutaneous T-cell lymphoma, but research has also reported elevated rates of other T-cell and related lymphomas in patients treated with the drug. If you used Dupixent and were later diagnosed with a T-cell lymphoma of any type, it is worth finding out whether you have a claim.
- No fee unless you recover
- 100% confidential
- Nationwide claims
- Consolidated in federal court
Understanding T-Cell Lymphomas
T-cell lymphomas are a group of cancers that begin in the T-cells of the immune system. They are a subset of non-Hodgkin lymphoma. Cutaneous T-cell lymphoma, which shows up primarily in the skin, is the form most directly tied to the Dupixent litigation, and its most common subtypes are mycosis fungoides and Sézary syndrome.
There are other T-cell lymphomas as well, including peripheral T-cell lymphoma and certain T-cell and NK-cell lymphomas that can affect the lymph nodes, blood, and other parts of the body. Research connected to Dupixent has reported increased risk across more than one of these categories, which is why the litigation may expand over time.
What the Research and the Litigation Cover
Several epidemiologic studies have reported a consistent association between Dupixent use and T-cell lymphomas. A 2024 cohort study reported more than a 300 percent higher risk of cutaneous T-cell lymphoma in treated patients. A 2025 study of asthma patients reported a nearly 400 percent higher risk of T-cell and NK-cell lymphomas, with some subtype risks reported between 450 and 500 percent. The lawsuits allege that the makers of Dupixent failed to warn patients and physicians about these risks.
The federal litigation, MDL No. 3180, currently centers on cutaneous T-cell lymphoma claims. The panel overseeing it has indicated it will consider other forms of T-cell lymphoma as additional cases are filed. If you were diagnosed with a T-cell lymphoma after using Dupixent and you are not sure whether it fits, the free review is the right place to find out.
Diagnoses These Claims May Cover
- Cutaneous T-cell lymphoma (CTCL)
- Mycosis fungoides
- Sézary syndrome
- Peripheral T-cell lymphoma
- Other T-cell or NK-cell lymphomas diagnosed after Dupixent use
You May Qualify If
- You used Dupixent (dupilumab), typically for three months or longer.
- You were later diagnosed with a T-cell lymphoma of any type.
- Your diagnosis came during or after your Dupixent treatment.
Not certain your diagnosis qualifies? Tell us what you know. Part of the free review is helping you figure that out.
Where the Cases Stand
On June 4, 2026, federal Dupixent T-cell lymphoma cases were consolidated into MDL No. 3180 in the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi. The defendants are Regeneron Pharmaceuticals and Sanofi-Aventis U.S. The litigation currently focuses on cutaneous T-cell lymphoma and may expand to cover other T-cell lymphomas as more cases are filed. No settlements have been reached, and no outcome is guaranteed.
Current as of June 2026. The litigation is active and ongoing. No settlements have been reached, and no outcome is guaranteed.
Ready to find out if you have a claim?
Take a few minutes to share your story. There is no cost and no obligation, and your information stays confidential.
Or call 800-280-0420